These experiments collectively suggest that the SLIT3/UBE2C/Wnt3A axis is crucially involved in promoting the progression of NSCLC, and that inhibition of Wnt signaling could improve the chemotherapy outcomes in NSCLC patients with SLIT3 deficiency. This evidence concerns the gene SLIT3 and non-small cell lung carcinoma.